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Abstract
Background: Before Pre-Exposure Prophylaxis (PrEP) was officially recommended and made available, a few surveys
among gay and bisexual men, and persons living with HIV/AIDS (PLWHA), identified an informal use of antiretrovirals
(ARVs) for PrEP among HIV-negative individuals. Before PrEP availability in Italy, we aimed to assess whether PLWHA in
Italy shared their ARVs with HIV-negative individuals, whether they knew people who were on PrEP, and describe the
level of awareness and discussion on this preventive measure among them and people in their close circle.
Methods: Two anonymous questionnaires investigating personal characteristics and PrEP awareness, knowledge,
and experience were proposed to HIV specialists and their patients on ARVs in a one-week, cross-sectional survey
(December 2013–January 2014). Among PLWHA, a Multivariable Logistic Regression analysis was conducted to identify
factors associated with PrEP discussion with peers (close circle and/or HIV associations), and experience (use in close circle
and/or personal ARV sharing).
Results: Eighty-seven specialists in 31 representative Infectious Diseases departments administered the questionnaire
to 1405 PLWHA. Among specialists, 98% reported awareness, 65% knew the dosage schedule, and 14% had previously
suggested or prescribed PrEP. Among PLWHA, 45.6% were somehow aware, discussed or had direct or indirect
experience of PrEP: 38% “had heard” of PrEP, 24% were aware of studies in HIV-negative individuals demonstrating a
risk reduction through the use of ARVs, 22% had discussed PrEP, 12% with peers; 9% reported PrEP use in close circle
and 1% personal ARV sharing. Factors predictive of either PrEP discussion with peers or experience differed between
men and women, but across all genders were mainly related to having access to information, with HIV association
membership being the strongest predictor.
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Conclusions: At a time and place where there were neither official information nor proposals or interventions to guide
public policies on PrEP in Italy, a significant number of PLWHA were aware of it, and approximately 10% reported PrEP
use in their close circle, although they rarely shared their ARVs with uninfected people for this purpose. Official policies
and PrEP availability, along with implementation programs, could avoid risks from uncontrolled PrEP procurement and
self-administration practices.
Keywords: Pre-Exposure Prophylaxis (PrEP), HIV prevention, Anti-HIV agents, Persons Living with HIV/AIDS (PLWHA),
HIV physicians
Background
The efficacy and safety of pre-exposure prophylaxis
(PrEP) with oral tenofovir disoproxil fumarate (TDF)
with or without emtricitabine (FTC) to prevent human
immunodeficiency virus (HIV) infection were clearly
demonstrated in randomized, blinded and placebo-
controlled trials, among men who have sex with men
(MSM) and transgender women, sexually active hetero-
sexual adults, and intravenous drug users (IVDU) [1–4].
Two European studies launched in 2012 gave further
evidence that daily or on demand PrEP confers high
protection against HIV in MSM when adherence is con-
sistent [5, 6].
On the basis of the resulting high-quality evidence, in
2012 the U.S. Food and Drug Administration (FDA) and
in 2016 the European Medicines Agency (EMA) ap-
proved tenofovir-emtricitabine (TDF–FTC, Truvada®)
for PrEP in adults at high risk for contracting HIV infec-
tion, and guidelines were issued recommending that oral
PrEP (containing TDF) should be offered as an add-
itional prevention choice for people at substantial risk of
HIV infection as part of combination prevention ap-
proaches [7–9].
However, outside the U.S. widespread uptake has not
been immediate. In Europe PrEP is not routinely recom-
mended and prescribed, and as of January 2017,
Truvada® for PrEP has been available only in France,
following a Temporary Recommendation for Use by the
French regulatory agency (ANSM), and in Switzerland.
Data from the U.S., Australia and France, however,
suggested an informal use of antiretrovirals (ARVs) for
PrEP among HIV-negative individuals before PrEP was
officially recommended and made available, as identified
through surveys of gay and bisexual men, and persons
living with HIV/AIDS (PLWHA) [10–12].
The National Institute for Infectious Diseases “L.
Spallanzani” (INMI) in Rome is the coordinating centre
of the Italian Registry of Antiretroviral Post-Exposure
Prophylaxis (IRAPEP), and is supporting studies and ini-
tiatives to introduce PrEP in national prevention plans.
Therefore, before PrEP was recommended and available
in Italy, a nationwide survey was launched by INMI, to as-
sess whether PLWHA in Italy shared ARV for PrEP with
uninfected people, and describe awareness and discussion
on PrEP in this population.
Methods
Study design
At the INMI, we adopted the design, and translated and
adapted the questionnaires (Additional file 1 a-d), used
for the PREVIC cross-sectional study conducted in
France [12], kindly provided by the PREVIC coordina-
tors. The survey involved PLWHA and their treating
HIV physicians in hospital and university/research de-
partments and Institutes of infectious diseases in Italy.
Before the beginning of the study, the translated ques-
tionnaires were pre-tested at INMI on patients partici-
pating in the mutual help group at the Psychology Unit
and on seven physicians of the AIDS Referral Unit, all
not participating in the study afterwards.
Physicians in HIV centers providing ARV treatment
were contacted by e-mail during the first week of
October 2013. They could participate in the study enrol-
ling through an online form.
Each specialist was invited to propose an anonymous
standardized questionnaire (Additional file 1 a-b) to all
PLWHA on ARVs for at least 3 months, consecutively
visited between 9 and 14 December 2013 or, if the spe-
cialist was unavailable in that week, between 13 and 18
January 2014. The questionnaire for PLWHA included
socio-demographic characteristics (gender, age group,
place of residence, socio-economic category), whether
the responder was a member or supporter of an associ-
ation for the fight against AIDS (HIV association), and
risk behaviors and clinical, virological and immuno-
logical status of the participants. A second section
included eight closed questions on PrEP, regarding:
awareness; discussion with their close circle (which
could include stable or occasional partners, immediate
family members, close friends, or community members),
physician or members of HIV associations; use in their
close circle or sharing personal ARVs for PrEP. The
questionnaire took approximately 10 min to be com-
pleted. The patients received no incentives to participate
in the survey.
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A second standardized questionnaire (Additional
file 1 c–d) was addressed to the participating HIV physi-
cians to obtain individual data (gender, age, and type of in-
stitution), whether the responder was a member or
supporter of an association for the fight against AIDS, out-
patients seen during the study week, and knowledge and
previous prescription of PrEP. Both questionnaires were
anonymously completed, and each paper form was then
placed in a sealed envelope and sent to the principal inves-
tigator. The datasets were enclosed (Additional file 2 a-b).
The study was approved by the INMI Ethics
Committee (n.56/2013), and by the ECs of the San
Raffaele Hospital (Milan), Fondazione Policlinico Tor
Vergata (Rome), Area Vasta Sud Est (Siena), Aziende
Sanitarie Umbria (Perugia); the remaining centres
adopted the INMI’s EC resolution.
Statistical analysis
Participating PLWHA were stratified according to gen-
der. We conducted univariate analyses to identify factors
associated with PrEP discussion and experience (χ2,
Fisher exact test), defined as follows: PrEP discussion
grouped discussion either with persons in the PLWHA
close circle or members of HIV associations, or both,
considered as peers; PrEP experience grouped use of
PrEP either in the PLWHA close circle or personal ARV
sharing, or both.
A Multivariable Logistic Regression (MLR) analysis
was obtained through stepwise backward elimination, in-
cluding the variables that showed significance in the uni-
variate model (p < .10). Gender and age group were
possibly forced into each regression model, and three
models (overall, female –F, male-M) were built. Trans-
gender PLWHA, representing around 1% of the overall
sample, were only included in the overall model. Statis-
tical analysis was performed with IBM® SPSS® Statistics
version 21.0 (Chicago, IL).
Results
HIV physicians and patients
Eighty-seven HIV physicians from 31 representative de-
partments of Infectious Diseases in 13 Regions partici-
pated in the study (centers participation rate, 22.2%);
56% were from a research institute/university. Women
represented 53%; most physicians were aged > 50 (55%),
70% were unit heads or staff. Eight percent were mem-
ber of a HIV association. Physicians reported awareness
of PrEP (98%), with 65% reporting knowledge of the
dosage schedule. Twelve (14%) had previously suggested
(n = 10) or prescribed (n = 2) PrEP, in serodiscordant
couples for conception (n = 9), subjects with multiple
partners (n = 1), or in case of nonconsistent condom use
(n = 2), with tenofovir alone (n = 1) or Truvada® (n = 11).
These HIV physicians saw a median number of 23 out-
patients during the study week (range 2–92). Overall,
they proposed the study to 1506 PLWHA: 63 refused
and 38 were eliminated because of inconsistencies in the
questionnaire. Of the 1405 PLWHA eventually enrolled,
they all filled the whole questionnaire: 71.8% were males
(HIV transmission route: homosexual intercourse 43%,
heterosexual intercourse 25%, IVDU 17%, not reported-
NR 15%), 27% females (heterosexual intercourse 59%,
homo-bisexual intercourse 6%, IVDU 15%, NR 20%),
1.2% transgender. Altogether, 17% were member of HIV
associations. Most (80%) reported undetectable viral
load; 24% were coinfected with hepatitis C virus. Eight
percent reported a sexually-transmitted infection over the
last 12 months. Over the last 3 months, 68% (n = 961) re-
ported sexual intercourse, 16% (n = 226) with multiple
partners; 19% did not use condoms with their stable unin-
fected partner or with casual partners.
Knowledge, discussion and use of PrEP
“Having heard” of PrEP was reported by 539 PLWHA
(38.4%), but of these, 337 were actually aware of studies
in HIV negative individuals demonstrating a risk reduc-
tion through the use of ARVs (24%). These were more
frequently member of HIV associations (27% vs 14%; OR
2.28, CI 95% 1.68–3.10, p < .001), and used condoms
with their stable partner (54% vs 43%; OR 1.56, 1.21–
2.01, p < .001).
Among all participants, 305 (21.7%) discussed PrEP
with someone, 166 of whom (12% of the whole popula-
tion) reported discussion with individuals of their close
circle or members of HIV associations. Regarding experi-
ence, 126 participants (9%) reported PrEP use in their
close circle, and 14 (1%) personal ARV sharing. Only 58
individuals (4.1%; 42 males, 3 transgender, 13 females)
overlapped between the two groups, having reported
either discussion with peers and use in close circle or
ARV sharing. Most persons reporting either discus-
sion or PrEP experience were males (75%), MSM
(45%), aged > 40 (65%), lived in a metropolitan area (50%)
and had a single partner over the last 3 months (50%).
In the MLR model, the following factors were found
to be associated with a greater likelihood of discussing
PrEP with peers: HIV association membership (All),
sexual activity (multiple partners, All), age group (30–
40 years, M-model), route of HIV transmission (homo/
bisexual intercourse, IVDU, M-model), occupation
(employee/intellectual worker, F-model), CD4 count
(< 200/mm3, F-model), and viral load (detectable, F-model)
(Table 1).
Factors associated with a greater likelihood of report-
ing PrEP experience were: gender (transgender, male),
HIV association membership (All), younger age (< 30,
30–40 years, M-model), route of HIV transmission
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(homo/bisexual intercourse, IVDU, M-model), ARV
changes over the last 12 months (M-model), sexual ac-
tivity (multiple partners, F-model), enrolling institution
(research institute, F-model), and viral load (detectable,
F-model) (Table 2).
Discussion
In spite of the lack of public information or regulation
on PrEP in Italy at the time of this study, 38% of the par-
ticipants were aware of PrEP, 24% knew the results of
the studies demonstrating a risk reduction through the
use of ARVs, 22% had discussed PrEP with their peers or
doctors, 9% had people in their close circle who used
PrEP, and 1% had shared their personal ARVs for PrEP
with someone.
Though the study was conducted in Italy 2 years after
the PREVIC Study, after FDA approved Truvada® for
PrEP in adults at high risk for contracting HIV infection,
and after the launch of two well-publicized PrEP studies
in Europe, these proportions are very similar to those
observed in France [12].
However, only some similarities were observed in the
two PLWHA populations (French and Italian) regarding
factors associated with a greater likelihood of discussing







N (%) AOR (95% CI) p-value n (%) AOR (95% CI) p-value n (%) AOR (95% CI) p-value
Age (years)
< 30 12 (16.7) 1.5 0.7–2.9 8 (17.8) 1.3 0.5–3.0 0.568
30–40 45 (16.7) 1.6 1.0–2.3 0.034 32 (18.1) 1.7 1.1–2.8 0.026
> 40 109 (10.2) 1 79 (10.0) 1
Socio-economic category
Without occupation 30 (11.3) 1 7 (6.2) 1 21 (14.8) 1
Farmers/Intermediary workers 47 (9.4) 0.9 0.5–1.4 0.659 12 (10.7) 1.7 0.6–4.7 0.316 33 (8.5) 0.6 0.3–1.1 0.087
Employee/Intellectual workers 72 (16.9) 1.7 1.0–2.7 0.036 19 (17.8) 3.8 1.4–10.2 0.007 53 (16.7) 1.2 0.6–2.1 0.608
Retired 17 (8.1) 0.8 0.4–1.6 0.549 5 (10.6) 1.7 0.5–6 0.395 12 (7.3) 0.6 0.3–1.3 0.189
Member of HIV associations
Yes 51 (21.3) 2.4 1.6–3.5 <0.001 11 (19.0) 2.4 1.1–5.4 0.028 37 (21.1) 2.4 1.6–3.8 <0.001
Undetectable HIV RNA
No 14 (20.3) 2.5 1.1–5.3 0.023
Route of HIV transmission
Heterosexual intercourse 41 (8.7) 1 19 (7.7) 1
Homo/Bisexual intercourse 74 (15.8) 1.7 1.1–2.6 0.015 66 (15.4) 1.8 1.0–3.1 0.041
Intravenous Drug Use 32 (14.0) 2.0 1.2–3.4 0.008 22 (12.9) 2.0 1.0–4.0 0.038
Other/unknown 19 (7.9) 1.0 0.5–1.7 0.967 12 (7.4) 1.0 0.5–2.2 0.915
CD4 count/mm3
< 200 21 (17.9) 2.1 1.2–3.7 0.009 7 (19.4) 2.9 1.0–8.5 0.050
200–499 45 (12.0) 1.2 0.8–1.8 0.325 12 (12.5) 1.5 0.7–3.6 0.308
500+ 75 (11.2) 1 16 (8.2) 1
NR/ND 25 (10.4) 1.2 0.7–2.0 0.501 8 (15.4) 2.1 0.8–5.8 0.144
Partners’ number (last 3 months)
No partner 39 (8.8) 1 14 (9.2) 1 25 (8.6) 1
Single partner 86 (11.7) 1.2 0.8–1.8 0.490 24 (11.2) 1.3 0.6–2.7 0.545 61 (11.8) 1.3 0.8–2.1 0.347
Multiple partners 41 (18.1) 1.7 1.0–2.9 0.042 5 (45.5) 8.9 2.1–37.7 0.003 33 (16.4) 1.6 0.9–3.0 0.096
AOR adjusted odds ratio, CI confidence interval, ART antiretroviral therapy, STI sexually transmitted infection
aIncluding Transgender persons (n = 4/17). Significant variables at univariate analysis (p < 0.100): Gender (forced variable); Age; Socio-economic category; Member
of HIV associations; Route of HIV transmission; CD4 count/mm3; STI (last 12 months); Partners’ number (last 3 months)
bSignificant variables at univariate analysis (p < 0.100): Age (forced variable); Socio-economic category; Member of HIV associations; Undetectable HIV RNA; CD4
count/mm3; Partners’ number (last 3 months)
cSignificant variables at univariate analysis (p < 0.100): Age; Place of residence; Socio-economic category; Member of HIV associations; Route of HIV transmission;
Partners’ number (last 3 months)
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PrEP with peers or having PrEP experience: among males,
HIV association membership and non-heterosexual route
of HIV transmission; and among females, having multiple
partners. Actually, in Italy, HIV association membership
was the strongest predictor of discussing and having a per-
sonal or a close experience of PrEP across the whole pa-
tient population (males, females and transgender persons),
thereby confirming the crucial role that associations play
in the spread of information [13]. Indeed, in our study,
factors predictive of either discussion or experience re-
garding PrEP seem mostly related to having access to in-
formation on this issue, especially among females. Other
factors seem to be related with the possibility of transmit-
ting the infection, i.e., having multiple partners among all
genders, route of HIV transmission among males, and
having a detectable viral load among females, though in a
previous study, the fear of infecting the partner among
women living with HIV in Italy was unrelated with viro-
logical control in plasma [14].
Also very similar were the proportions of French and
Italian HIV physicians aware of PrEP, knowing the dos-
age schedule, and having actually prescribed PrEP. Data
on PrEP knowledge, though not further assessed, are
consistent with previous results among Italian HIV







N (%) AOR (95% CI) p-value N (%) AOR (95% CI) p-value N (%) AOR (95% CI) p-value
Gender
Female 24 (6.3) 1 – – – –
Male 111 (11.0) 1.5 0.9–2.6 0.088 – – – –
Transgender 5 (29.4) 3.4 1.0–11.4 0.049 – – – –
Age (years)
< 30 12 (16.7) 2.1 1.1–4.2 0.031 9 (20.0) 2.3 1.0–5.0 0.048
30–40 33 (12.3) 1.6 1.0–2.5 0.034 25 (14.1) 1.8 1.1–3.0 0.026
> 40 95 (8.9) 1 77 (9.8) 1
Enrolling centre
General hospital 32 (7.3) 1 3 (2.5) 1
Research Institute 57 (13.5) 1.9 1.2–3.1 0.006 12 (11.2) 5.5 1.4–21.6 0.014
University Institute 51 (9.4) 1.3 0.8–2.1 0.244 9 (5.9) 2.3 0.6–9.1 0.250
Member of HIV associations
Yes 42 (17.5) 2.2 1.5–3.3 <0.001 6 (10.3) 2.6 0.9–7.6 0.074 33 (18.9) 2.2 1.4–3.4 0.001
Route of HIV transmission
Heterosexual intercourse 27 (5.7) 1 16 (6.5) 1
Homo/Bisexual intercourse 57 (12.2) 1.7 1.0–2.8 0.061 49 (11.4) 1.6 0.9–3.0 0.109
Intravenous Drug Use 34 (14.8) 2.6 1.5–4.5 0.001 29 (17.0) 3.1 1.6–5.9 0.001
Other/unknown 22 (9.2) 1.5 0.8–2.8 0.172 17 (10.4) 1.7 0.8–3.5 0.151
Change ART (last 12 months)
Yes 32 (14.5) 1.5 0.9–2.3 0.102
Undetectable HIV RNA
No 39 (13.7) 1.6 1.1–2.5 0.018 10 (14.5) 4.5 1.8–11.3 0.002
Partners’ number (last 3 months)
No partner 36 (8.1) 7 (4.6) 1
Single partner 70 (9.5) 13 (6.0) 1.5 0.6–4.0 0.421
Multiple partners 34 (15.0) 4 (36.4) 17.5 3.6–84.9 <0.001
AOR adjusted odds ratio, CI Confidence Interval, ART antiretroviral therapy, STI sexually transmitted infection
aIncluding Transgender persons (n = 5/17). Significant variables at univariate analysis (p < 0.100): Gender; Age; Enrolling centre; Member of HIV associations; Route
of HIV transmission; Undetectable HIV RNA; Partners’ number (last 3 months)
bSignificant variables at univariate analysis (p < 0.100): Age (forced variable); Enrolling centre; Member of HIV associations; Route of HIV transmission; Undetectable
HIV RNA; CD4 count/mm3; STI (last 12 mos); Partners’ number (last 3 months)
cSignificant variables at univariate analysis (p < 0.100): Age; Enrolling centre; Member of HIV associations; Route of HIV transmission; Change ART (last 12 months)
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specialists [15]. Among patients, discussion with their
HIV physician was reported by 15%, though we excluded
this item from the MLR analysis as in Italy we had ob-
served conflicting results regarding attitudes towards
PrEP prescription among HIV physicians [15, 16].
These results cannot be considered fully representative
of the whole population on ARVs in Italy, even if the
centres which contributed are among those which treat
the highest proportion of PLWHA. However, our results
are in line with those of the “Flash PrEP” survey con-
ducted almost contemporarily to characterize informal
PrEP use in France [17]. Moreover, a significant increase
in awareness and attitude is likely to have occurred after
the widely publicized appearance of the results from
IPERGAY [5] and PROUD [6], the international guide-
lines, and the EMA approval, so that any further delay
in incorporating PrEP in national prevention protocols
might result in dangerous practices. HIV seroconversion
while using non-prescribed ARVs for PrEP has been re-
ported, and uncontrolled use might undermine the pro-
tective benefits of PrEP [18].
As a biomedical HIV prevention technology, PrEP
opens up opportunities for expanded autonomy in man-
aging one’s own sexual health, and might re-balance
structural asymmetries through shifting the control of
sexual risk from the HIV-positive to the HIV-negative
partner, a fact especially important for women [19]. PrEP
also prefigures a different kind of user of sexual health
services, one more mobile and active than the traditional
idea of patient allows [20]. Therefore, it should not be
unexpected that 45.6% of PLWHA were somehow
aware, discussed or had direct or indirect experience of
PrEP at a time and place where there were neither infor-
mation nor proposals or interventions to guide public
policies in this regard. This underlines that the temporal
rhythms of connection between affected communities
and public health systems should be synchronized to
avoid uncontrolled procurement practices and self-
administration of ARVs amongst HIV-exposed persons.
Conclusions
These results suggest that although PrEP is not officially
provided in Italy, a significant number of PLWHA are
aware of it, and approximately 10% report PrEP use in
their close circle. While PLWHA seem to rarely share
their ARVs with uninfected people for this purpose, as-
sociations representing the LGBT Community recently
launched an alert regarding “online shopping” and the
consequent lack of appropriate clinical and serological
monitoring [21]. In the absence of national implementa-
tion programs, these findings alert towards the risks
deriving from uncontrolled PrEP procurement and self-
administration practices, and call for official policies on
PrEP offer and use at a country level.
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